|
|
|
|
|
|
by refurb
1970 days ago
|
|
|
The hepatitis C cures was massively profitable. Gilead paid $11B for Pharmasset’s portfolio and everyone said they were dumb. They then had sales of $10.4B in the first year on the market. That’s one year and one drug (they’ve developed newer drugs and launched those too). |
|
|